Open an account

Silo Pharma

SILO · NASDAQ

$1.20+$0.07 (+6.19%)TodayMarket closed ·
Prev close $1.13

About SILO

Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. The company is headquartered in Sarasota, Florida. The company went IPO on 2012-01-05. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.

Employees
3
Headquarters
Sarasota, Florida
Listed
Jan 5, 2012
Sector
Health Care
Industry
Biotechnology
Website
silopharma.com

SILO key statistics

Market cap
1.91M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
108.74K
Volume
9.52K
Open price
$1.14
High today
$1.21
Low today
$1.15
52 Week high
$10.43
52 Week low
$1.10

Silo Pharma (SILO) at a glance

Silo Pharma (SILO) last traded at $1.20, with a market cap of 1.91M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.15 and $1.21. The current price is 4.5% above the day's low and 0.8% below its high.

Volume so far is 9.52K shares, below the average of 108.74K shares a day.

Over the past year Silo Pharma has ranged from $1.10 to $10.43, and now sits 1% of the way up that range.

SILO news

  • Press releaseGlobe Newswire

    Silo Pharma’s QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility

  • Press releaseGlobe Newswire

    Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio

  • Press releaseGlobe Newswire

    Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releaseGlobe Newswire

    Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment

  • Press releaseGlobe Newswire

    Silo Pharma Granted European Patent Covering Novel PTSD Therapy

  • 12 Health Care Stocks Moving In Friday's After-Market Session

Similar companies

Companies in the same industry as Silo Pharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.